The 12 closest competitors and alternatives to CureGene Pharmaceutical among pharmaceuticals companies — ranked by similarity to what CureGene Pharmaceutical actually does, not by market-cap band.
Subscribe to see CureGene Pharmaceutical’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Shanghai CureGene Pharmaceutical Co., Ltd. is a biopharmaceutical company founded in Zhangjiang, Shanghai, in 2018. It specializes in developing state-of-the-art medications and has built a globally leading targeted prodrug platform.
CureGene Pharmaceutical is a pharmaceuticals company headquartered in China. It has raised at least $60.8M across the 4 funding rounds on record, 2 of them with a disclosed amount. Its most recent funding round, Series B, raised $47M in May 2026. Xcout tracks 1 named person at CureGene Pharmaceutical, including Gongxin He (Founder and CEO).
At least $60.8M raised across the 4 rounds on record (2 with a disclosed amount). Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $47M | 6 named | |
| Series B | $13.8M | 6 named | |
| — | Undisclosed | 5 named | |
| Series B | Undisclosed | 6 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Ranked by semantic similarity — how close each company is to CureGene Pharmaceutical by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar pharmaceuticals company
Danqing Pharmaceuticals is a pharmaceutical company headquartered in Beijing with a U.S. subsidiary in Boston. The company focuses on first-in-class drug discovery and development in oncology, targeting therapeutic areas such as breast, gynecological, and gastrointestinal cancers.
Similar pharmaceuticals company
Fog Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize them. The company was founded by Gregory L. Verdine, WeiQing Zhou and David Philip Lane in 2015 and is headquartered in Cambridge, MA.
Similar pharmaceuticals company
Tyra Biosciences, Inc. is a preclinical biopharmaceutical company focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology. Its flagship product candidate, TYRA-300, is a highly selective inhibitor of fibroblast growth factor receptor (FGFR)3, specifically engineered for the treatment of muscle-invasive bladder cancer. Beyond this, the company is advancing a pipeline of programs addressing other critical conditions, including FGFR2-related intrahepatic cholangiocarcinoma, FGFR3-associated achondroplasia, REarranged during transfection (RET) kinase aberrations, and various FGFR4-driven cancers. Tyra also leverages its proprietary SNAP platform, designed to accelerate structural drug design through an iterative molecular 'snapshot' approach. Founded in 2018, Tyra Biosciences maintains its headquarters in Carlsbad, California.
Similar pharmaceuticals company
Cao Pharmaceuticals Inc. develops anti-cancer drugs utilizing natural anti-cancer compounds. The company focuses on research, product pipelines, and developing lead drug candidates for cancer treatment.
Pharmaceuticals and Biotechnology
Anagenex is a biotechnology company that uses high-throughput experimentation, functional screening, and machine learning to discover small-molecule drug candidates. It focuses on challenging drug targets and works with biopharmaceutical companies as well as developing its own therapeutic programs.
Biotechnology
Chimagen Biosciences is a biopharmaceutical company headquartered in Shanghai, China, founded in July 2016. The company specializes in multi-specific antibody therapeutics and built the proprietary TRIAD platform for engineering.
Biotechnology
Vibrant Therapeutics is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts, with operations in China. Founded in July 2019, the firm focuses on revolutionizing protein drug discovery and developing next-generation prodrugs with precise targeting.
Biotechnology
Coherent Biopharma is a biotechnology research and pharmaceutical company founded by Robert Huang. Headquartered in Suzhou, China, the firm focuses on targeted protein degradation and advanced drug discovery in oncology and biotherapeutics.
Healthcare
VelaVigo is a leading biotech company specializing in drug discovery and development. The company maintains its global R&D headquarters in Shanghai, China, alongside clinical and operational footprints in Boston, United States.
Biotechnology
Cime Therapeutics Inc. is a chemistry-first company that provides an automated synthesis platform integrating artificial intelligence and machine learning for drug discovery. The company serves the pharmaceutical and biotechnology sectors by producing novel therapeutic molecules, such as small molecules, molecular glues, and covalent compounds, at high speed and scale.
Biotech
HitGen Inc. is a biopharmaceutical and contract research company that provides drug discovery services and technologies to the global pharmaceutical and biotechnology industry. It specializes in DNA-encoded library (DEL) technology, fragment-based drug discovery, structure-based drug design, and oligonucleotide-based therapeutics to discover novel small molecules and therapeutics for global clients and internal pipelines.
Biotechnology
CuraGen AI (CuraGen Corporation) is a biotechnology company headquartered in Branford, Connecticut, that designs disease-modifying small molecules and accelerates target-to-lead discovery for hard-to-treat diseases.
Search any company we track to see its competitive set.
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
Funding, investors, tech stack, hiring signals, leadership and corporate events — for CureGene Pharmaceuticaland every competitor above — in one live dashboard.
Subscribe to Xcout Intel →